Tarextumab (OMP‐59R5) is a human IgG2 antibody with inhibition on both Notch2 and Notch3 and has shown encouraging antitumor efficacy in small cell lung cancer (SCLC). This evidence concerns the gene NOTCH3 and small cell lung carcinoma.